By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Ceptaris Therapeutics, Inc. 

3701 Market Street, 4th Floor

Lexington  Kentucky    U.S.A.
Phone: n/a Fax:



Company News
Ceptaris Therapeutics, Inc. Receives FDA Approval for VALCHLOR™ (mechlorethamine) Lymphoma Gel 8/26/2013 6:46:27 AM
Actelion Pharmaceuticals US, Inc. (ATLN.VX) Nabs Ceptaris Therapeutics, Inc. in $250 Million Buyout Deal 8/1/2013 7:14:58 AM
Ceptaris Therapeutics, Inc. Seeking FDA Approval of Drug 3/1/2013 8:25:10 AM
Ceptaris Therapeutics, Inc. Announces Publication in JAMA Dermatology of Positive Clinical Results for Mechlorethamine Gel in Early Stage Mycosis Fungoides, the Most Common Type of Cutaneous T-Cell Lymphoma 1/30/2013 9:50:27 AM
Ceptaris Therapeutics, Inc. Secures $10 Million in Series D-1 Financing 6/5/2012 7:36:17 AM
Ceptaris Therapeutics, Inc. Secures $15 Million in Venture Debt Financing 2/21/2012 7:28:38 AM
Ceptaris Therapeutics, Inc. Receives EMA Orphan Drug Designation for Proprietary Mechlorethamine Gel 1/18/2012 6:52:10 AM
Yaupon Therapeutics Inc. Changes Name to Ceptaris Therapeutics, Inc. 1/5/2012 7:12:14 AM
FDA Accepts Filing of New Drug Application (NDA) for Yaupon Therapeutics Inc.'s Proprietary Gel Formulation of Mechlorethamine Hydrochloride 10/4/2011 8:46:14 AM
Yaupon Therapeutics Inc. Secures $14.4 Million in Series D Financing 8/11/2011 7:19:35 AM